angiocal protein

an engineered anticalin and VEGF-A antagonist that is based on tear lipocalin

Also Known As:

PRS-050

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 01/01/2013 - "Patients with advanced solid tumors received PRS-050 at 0.1 mg/kg to 10 mg/kg by IV in successive dosing cohorts according to the 3+3 escalation scheme. " 01/01/2013 - "First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors."

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)